Vor Biopharma Inc
VOR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.07B
Close$
$39.86
107.1% upside
Current Fair Value
107.1% upsideUndervalued by 107.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $1.07 Billion |
|---|---|
| Enterprise Value | $961.40 Million |
| Earnings per Share | $-70.5 |
| Beta | 1.78 |
| Outstanding Shares | 59,669,730 |
Return
| Return on Equity | -676.20% |
|---|---|
| Return on Assets | 281.41% |
| Return on Invested Capital | -45.09% |
Valuation & Multiples
| P/E Ratio | 0.07 |
|---|---|
| PEG | -0.07 |
| Price to Sales | - |
| Price to Book Ratio | -4.81 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -4.67 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
October 30, 2026
EPS Estimate
$-1.08
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.84
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.26%▼ 89.29% |
|---|---|
| Total Invested | $2.72M▼ 99.70% |
| Investors Holding | 24▼ 81.00% |
About Vor Biopharma Inc
88 employees
Vor Biopharma is a cell therapy company that aims to transform the lives of cancer patients by pioneering engineered hematopoietic stem cell (eHSC) therapies to create next-generation, treatment-resistant transplants that unlock the pote...